You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
|
|---|---|
| Published in |
Lancet Oncology, August 2012
|
| DOI | 10.1016/s1470-2045(12)70265-6 |
| Pubmed ID | |
| Authors |
Annika Malmström, Bjørn Henning Grønberg, Christine Marosi, Roger Stupp, Didier Frappaz, Henrik Schultz, Ufuk Abacioglu, Björn Tavelin, Benoit Lhermitte, Monika E Hegi, Johan Rosell, Roger Henriksson, for the Nordic Clinical Brain Tumour Study Group |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 20% |
| United Kingdom | 1 | 20% |
| Spain | 1 | 20% |
| Unknown | 2 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 80% |
| Science communicators (journalists, bloggers, editors) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 773 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | <1% |
| Germany | 2 | <1% |
| France | 2 | <1% |
| Italy | 2 | <1% |
| Brazil | 2 | <1% |
| Uruguay | 1 | <1% |
| Switzerland | 1 | <1% |
| Belgium | 1 | <1% |
| United Kingdom | 1 | <1% |
| Other | 2 | <1% |
| Unknown | 753 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 116 | 15% |
| Student > Ph. D. Student | 101 | 13% |
| Other | 74 | 10% |
| Student > Bachelor | 63 | 8% |
| Student > Master | 61 | 8% |
| Other | 196 | 25% |
| Unknown | 162 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 404 | 52% |
| Biochemistry, Genetics and Molecular Biology | 38 | 5% |
| Neuroscience | 33 | 4% |
| Agricultural and Biological Sciences | 26 | 3% |
| Nursing and Health Professions | 9 | 1% |
| Other | 63 | 8% |
| Unknown | 200 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 November 2023.
All research outputs
#2,787,039
of 26,017,215 outputs
Outputs from Lancet Oncology
#2,532
of 6,958 outputs
Outputs of similar age
#18,228
of 189,300 outputs
Outputs of similar age from Lancet Oncology
#16
of 88 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,958 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.3. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 189,300 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 88 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.